Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VENITI, Inc.
Following Positive IIb Study Data, Can 180 Life Sciences Clear The Next Regulatory Hurdle?
180 Life Sciences has found that adalimumab can effectively treat nodule hardness and size in Dupuytren’s disease during a Phase IIb study. But, the company’s CEO Jim Woody tells Generics Bulletin, regulators in the UK and US have requested more information before they will press on with authorization.
Tech Transfer Roundup: Santhera Exits Congenital Muscular Dystrophy Pact To Focus On DMD
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 2: Deal Making, M&A And Financial Markets
Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.